| Mrs Christel Lynn Labarge Burke, CRNA | |
|
650 Huebner Rd, Fort Riley, KS 66442-4030 | |
| (785) 802-5216 | |
| Not Available |
| Full Name | Mrs Christel Lynn Labarge Burke |
|---|---|
| Gender | Female |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 650 Huebner Rd, Fort Riley, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386892206 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 55667 (Kansas) | Primary |
| Entity Name | Kansas Medical Clinic Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508877523 PECOS PAC ID: 4981592334 Enrollment ID: O20040308000496 |
News Archive
The National Science Advisory Board for Biosecurity's (NSABB) "reversal on publishing two controversial H5N1 studies is poised to shift discussions on the topic that continue in London this week, as more participants in the debate weigh in following the March 30 announcement," CIDRAP News reports.
Now, a team of researchers at the University of Alberta in Canada has identified viral inhibitors that they claim are potential candidates as a treatment for COVID-19. The team is set to launch clinical trials of the drug that is used as a treatment for a type of coronavirus in cats.
Nearly a third of older adults have received a prescription for an opioid pain medicine in the past two years, but many of them didn't get enough counseling about the risks that come with the potent painkillers, how to reduce their use, when to switch to a non-opioid option, or what to do with leftover pills, a new poll finds.
Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology.
Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that a scientific paper co-authored by Ryo Kubota, M.D., Ph.D., chairman, president and chief executive officer of Acucela, has been published in Experimental Eye Research. The paper, "Visual Cycle Modulation in Neurovascular Retinopathy" was also co-authored by scientists from Children's Hospital and Harvard Medical School in Boston and demonstrates for the first time the impact of treatment with a visual cycle modulator (VCM) on retinopathy in an immature eye.
› Verified 8 days ago
| Entity Name | Cloud County Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003950189 PECOS PAC ID: 4082522859 Enrollment ID: O20050222000898 |
News Archive
The National Science Advisory Board for Biosecurity's (NSABB) "reversal on publishing two controversial H5N1 studies is poised to shift discussions on the topic that continue in London this week, as more participants in the debate weigh in following the March 30 announcement," CIDRAP News reports.
Now, a team of researchers at the University of Alberta in Canada has identified viral inhibitors that they claim are potential candidates as a treatment for COVID-19. The team is set to launch clinical trials of the drug that is used as a treatment for a type of coronavirus in cats.
Nearly a third of older adults have received a prescription for an opioid pain medicine in the past two years, but many of them didn't get enough counseling about the risks that come with the potent painkillers, how to reduce their use, when to switch to a non-opioid option, or what to do with leftover pills, a new poll finds.
Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology.
Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that a scientific paper co-authored by Ryo Kubota, M.D., Ph.D., chairman, president and chief executive officer of Acucela, has been published in Experimental Eye Research. The paper, "Visual Cycle Modulation in Neurovascular Retinopathy" was also co-authored by scientists from Children's Hospital and Harvard Medical School in Boston and demonstrates for the first time the impact of treatment with a visual cycle modulator (VCM) on retinopathy in an immature eye.
› Verified 8 days ago
| Entity Name | Sweet Dreams Anesthesia Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508133497 PECOS PAC ID: 0042477705 Enrollment ID: O20191206000961 |
News Archive
The National Science Advisory Board for Biosecurity's (NSABB) "reversal on publishing two controversial H5N1 studies is poised to shift discussions on the topic that continue in London this week, as more participants in the debate weigh in following the March 30 announcement," CIDRAP News reports.
Now, a team of researchers at the University of Alberta in Canada has identified viral inhibitors that they claim are potential candidates as a treatment for COVID-19. The team is set to launch clinical trials of the drug that is used as a treatment for a type of coronavirus in cats.
Nearly a third of older adults have received a prescription for an opioid pain medicine in the past two years, but many of them didn't get enough counseling about the risks that come with the potent painkillers, how to reduce their use, when to switch to a non-opioid option, or what to do with leftover pills, a new poll finds.
Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology.
Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that a scientific paper co-authored by Ryo Kubota, M.D., Ph.D., chairman, president and chief executive officer of Acucela, has been published in Experimental Eye Research. The paper, "Visual Cycle Modulation in Neurovascular Retinopathy" was also co-authored by scientists from Children's Hospital and Harvard Medical School in Boston and demonstrates for the first time the impact of treatment with a visual cycle modulator (VCM) on retinopathy in an immature eye.
› Verified 8 days ago
| Entity Name | Herington Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447829536 PECOS PAC ID: 8527469188 Enrollment ID: O20210713002964 |
News Archive
The National Science Advisory Board for Biosecurity's (NSABB) "reversal on publishing two controversial H5N1 studies is poised to shift discussions on the topic that continue in London this week, as more participants in the debate weigh in following the March 30 announcement," CIDRAP News reports.
Now, a team of researchers at the University of Alberta in Canada has identified viral inhibitors that they claim are potential candidates as a treatment for COVID-19. The team is set to launch clinical trials of the drug that is used as a treatment for a type of coronavirus in cats.
Nearly a third of older adults have received a prescription for an opioid pain medicine in the past two years, but many of them didn't get enough counseling about the risks that come with the potent painkillers, how to reduce their use, when to switch to a non-opioid option, or what to do with leftover pills, a new poll finds.
Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology.
Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that a scientific paper co-authored by Ryo Kubota, M.D., Ph.D., chairman, president and chief executive officer of Acucela, has been published in Experimental Eye Research. The paper, "Visual Cycle Modulation in Neurovascular Retinopathy" was also co-authored by scientists from Children's Hospital and Harvard Medical School in Boston and demonstrates for the first time the impact of treatment with a visual cycle modulator (VCM) on retinopathy in an immature eye.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Christel Lynn Labarge Burke, CRNA 819 Crestview Dr, Junction City, KS 66441-3429 Ph: (785) 802-5216 | Mrs Christel Lynn Labarge Burke, CRNA 650 Huebner Rd, Fort Riley, KS 66442-4030 Ph: (785) 802-5216 |
News Archive
The National Science Advisory Board for Biosecurity's (NSABB) "reversal on publishing two controversial H5N1 studies is poised to shift discussions on the topic that continue in London this week, as more participants in the debate weigh in following the March 30 announcement," CIDRAP News reports.
Now, a team of researchers at the University of Alberta in Canada has identified viral inhibitors that they claim are potential candidates as a treatment for COVID-19. The team is set to launch clinical trials of the drug that is used as a treatment for a type of coronavirus in cats.
Nearly a third of older adults have received a prescription for an opioid pain medicine in the past two years, but many of them didn't get enough counseling about the risks that come with the potent painkillers, how to reduce their use, when to switch to a non-opioid option, or what to do with leftover pills, a new poll finds.
Early use of available heart failure drugs slows the progressive decline in heart function before symptoms are apparent in boys and young men with Duchenne muscular dystrophy (DMD), according to a new study published online by The Lancet Neurology.
Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that a scientific paper co-authored by Ryo Kubota, M.D., Ph.D., chairman, president and chief executive officer of Acucela, has been published in Experimental Eye Research. The paper, "Visual Cycle Modulation in Neurovascular Retinopathy" was also co-authored by scientists from Children's Hospital and Harvard Medical School in Boston and demonstrates for the first time the impact of treatment with a visual cycle modulator (VCM) on retinopathy in an immature eye.
› Verified 8 days ago
Jason A Perez, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 650 Huebner Rd., Fort Riley, KS 66442 Phone: 785-239-7667 | |
Nicholas Adam Isakson, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 650 Huebner Rd, Fort Riley, KS 66442 Phone: 785-239-7151 Fax: 785-240-7438 | |
Dr. Jeffrey Burke, DNP, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 650 Huebner Rd, Fort Riley, KS 66442 Phone: 785-239-7391 | |
Phillip John Noble, DNP, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 650 Huebner Rd, Fort Riley, KS 66442 Phone: 716-359-5712 | |
Maevelyn Andalis O'donnell, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 650 Huebner Rd, Fort Riley, KS 66442 Phone: 337-378-5585 | |
Mrs. Heather Lynnette Frisbie, C.R.N.A. Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 650 Huebner Rd, Fort Riley, KS 66442 Phone: 785-239-7151 |